Lumosa to commence a multi-dose Phase 1 trial right after the single-dose Phase 2 to expand stroke treatment methodology

LT3001 is a novel treatment for acute ischemic stroke (AIS), currently under development by Lumosa Therapeutics (Lumosa). The company will proceed with a multi-dose and drug-drug-interaction Phase I trial right after the enrollment completion of the single-dose Phase II study for LT3001. The study will help Lumosa to obtain safety data and pharmacokinetic parameters as the administration frequency is increased, to establish foundations for the coming Phase II multiple-dose trial.

Enrollment Completed for 1st Phase 2 Trial for LT3001

Lumosa is pleased to announce that the company has completed the #enrollment of its first Phase 2 clinical trial for #LT3001, a new chemical entity for the treatment of acute ischemic stroke. The data is expected to come out in Q1 of 2021.

LT3001 Received IND Approval from China's NMPA

Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its China partner Shanghai Pharmaceutical Holding (SHP) has received the IND approval from China’s NMPA for the lead drug candidate, LT3001,  a novel treatment for acute ischemic stroke.  A phase 2 clinical study is currently on-going in the US and Taiwan. Once China studies are initiated, the clinical trials from Chinese sites will contribute additional data to accelerate LT3001 towards market approval.

Patent for Lumosa's Extended-Release Analgesic Granted by Taiwan IPO

(August 10, 2020; Taipei) Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced today the granting of formulation patent for its extended-release analgesic injection, LT1001 (brand name: Naldebain®); the patent is valid until 2036.

The US FDA has granted the Orphan Drug Status to Lumosa's LT2003, an anti-tumor targeting fusion protein, for the treatment of pancreatic cancer

The US FDA Has Granted the Orphan Drug Status to Lumosa’s LT2003, an Anti-tumor Targeting Fusion Protein, for the Treatment of Pancreatic Cancer

Lumosa received LT5001 IND approval from TFDA for the treatment of uremic pruritus

Lumosa Therapeutics (Lumosa; code:6535.TWO) announced IND approval by the Taiwan FDA (TFDA) for the phase Ib/II study of its LT5001, a new drug under development for the treatment of uremic pruritus. The company will soon proceed with the phase Ib trial in Taiwan, which is expected to be completed within one year after initiation. Around 40% of hemodialysis patients with chronic kidney disease suffer moderate to severe uremic pruritus. These patients will benefit from LT5001 when it reaches market in the future.